AR096433A1 - Método de tratamiento del cáncer y uso - Google Patents

Método de tratamiento del cáncer y uso

Info

Publication number
AR096433A1
AR096433A1 ARP140102081A ARP140102081A AR096433A1 AR 096433 A1 AR096433 A1 AR 096433A1 AR P140102081 A ARP140102081 A AR P140102081A AR P140102081 A ARP140102081 A AR P140102081A AR 096433 A1 AR096433 A1 AR 096433A1
Authority
AR
Argentina
Prior art keywords
cancer treatment
human
trioxo
pyrido
phenylamino
Prior art date
Application number
ARP140102081A
Other languages
English (en)
Inventor
Michael Richards Eric
R Hamid Mohammed
Behbahani Roya
R W Streit Michael
A Patel Kiran
Ouellet Daniele
Ann Rogan Debra
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of AR096433A1 publication Critical patent/AR096433A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un método para tratar el cáncer en un ser humano que lo necesite, que comprende la administración in vivo de una cantidad terapéuticamente eficaz de un compuesto seleccionado de N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-iI]fenil}acetamida, o una de sus sales o solvatos farmacéuticamente aceptables, a dicho ser humano.
ARP140102081A 2013-05-28 2014-05-26 Método de tratamiento del cáncer y uso AR096433A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361827940P 2013-05-28 2013-05-28

Publications (1)

Publication Number Publication Date
AR096433A1 true AR096433A1 (es) 2015-12-30

Family

ID=50884976

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102081A AR096433A1 (es) 2013-05-28 2014-05-26 Método de tratamiento del cáncer y uso

Country Status (4)

Country Link
AR (1) AR096433A1 (es)
TW (1) TW201536292A (es)
UY (1) UY35587A (es)
WO (1) WO2014191920A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka

Also Published As

Publication number Publication date
TW201536292A (zh) 2015-10-01
WO2014191920A1 (en) 2014-12-04
UY35587A (es) 2014-12-31

Similar Documents

Publication Publication Date Title
IL288231A (en) An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CR20160130A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
ECSP14017586A (es) Derivados de tetrahidro-quinazolinona
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
GB2583606C (en) Indoleamine 2,3-Dioxygenase inhibitors and use of same in medicine
AR096433A1 (es) Método de tratamiento del cáncer y uso
AR103484A1 (es) Triptólido y sus derivados en el tratamiento de tumores y patologías precancerosas de la piel
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
AR095890A1 (es) Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia
ES2548927B1 (es) Derivados de purina como inhibidores de Dapk-1
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario

Legal Events

Date Code Title Description
FB Suspension of granting procedure